Which has preferable earnings and valuation, SN or CTEC?

Smith & Nephew has higher revenue and earnings than ConvaTec Group. ConvaTec Group is trading at a lower price-to-earnings ratio than Smith & Nephew, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Smith & Nephew £7.08B 1.63 £382.79M £27.77 37.88 ConvaTec Group £2.49B 1.77 £188.35M £8.60 26.19

Does the media favor SN or CTEC?

In the previous week, Smith & Nephew and Smith & Nephew both had 2 articles in the media. ConvaTec Group's average media sentiment score of 0.51 beat Smith & Nephew's score of 0.33 indicating that ConvaTec Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Smith & Nephew 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ConvaTec Group 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, NIOX or SN?

NIOX Group has higher earnings, but lower revenue than Smith & Nephew. Smith & Nephew is trading at a lower price-to-earnings ratio than NIOX Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NIOX Group £48.70M 5.84 £995.88M £1.64 41.22 Smith & Nephew £7.08B 1.63 £382.79M £27.77 37.88

Is NIOX or SN more profitable?

NIOX Group has a net margin of 14.37% compared to Smith & Nephew's net margin of 10.08%. Smith & Nephew's return on equity of 12.25% beat NIOX Group's return on equity. Company Net Margins Return on Equity Return on Assets NIOX Group 14.37% 10.14% 3.95% Smith & Nephew 10.08% 12.25% 4.51%

Do analysts rate TSTL or SN?

Smith & Nephew has a consensus target price of GBX 1,310, suggesting a potential upside of 24.52%. Given Smith & Nephew's stronger consensus rating and higher possible upside, analysts plainly believe Smith & Nephew is more favorable than Tristel. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tristel 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Smith & Nephew 0 Sell rating(s) 6 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has preferable valuation and earnings, TSTL or SN?

Smith & Nephew has higher revenue and earnings than Tristel. Tristel is trading at a lower price-to-earnings ratio than Smith & Nephew, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tristel £49.54M 3.98 £6.54M £16.24 25.31 Smith & Nephew £7.08B 1.63 £382.79M £27.77 37.88

Is TSTL or SN more profitable?

Tristel has a net margin of 15.88% compared to Smith & Nephew's net margin of 10.08%. Tristel's return on equity of 23.64% beat Smith & Nephew's return on equity. Company Net Margins Return on Equity Return on Assets Tristel 15.88% 23.64% 9.89% Smith & Nephew 10.08% 12.25% 4.51%

Which has preferable earnings and valuation, SN or SPEC?

Smith & Nephew has higher revenue and earnings than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than Smith & Nephew, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Smith & Nephew £7.08B 1.63 £382.79M £27.77 37.88 INSPECS Group £191.70M 0.53 -£4.11M -£9.40 N/A

Smith & Nephew (SN) Competitors

GBX 1,052 -10.50 (-0.99%)

As of 09/3/2026

Compare

SN vs. CTEC, AMS, NIOX, TSTL, and SPEC

Should you buy Smith & Nephew stock or one of its competitors? Smith & Nephew's main competitors and comparable companies include ConvaTec Group (CTEC), Advanced Medical Solutions Group (AMS), NIOX Group (NIOX), Tristel (TSTL), and INSPECS Group (SPEC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment & supplies" industry.

How does Smith & Nephew compare to ConvaTec Group?

Smith & Nephew (LON:SN) and ConvaTec Group (LON:CTEC) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment.

Smith & Nephew pays an annual dividend of GBX 29 per share and has a dividend yield of 2.8%. ConvaTec Group pays an annual dividend of GBX 6.77 per share and has a dividend yield of 3.0%. Smith & Nephew pays out 104.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. ConvaTec Group pays out 78.7% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. ConvaTec Group is clearly the better dividend stock, given its higher yield and lower payout ratio.

Smith & Nephew currently has a consensus price target of GBX 1,310, indicating a potential upside of 24.52%. ConvaTec Group has a consensus price target of GBX 306, indicating a potential upside of 35.88%. Given ConvaTec Group's stronger consensus rating and higher possible upside, analysts plainly believe ConvaTec Group is more favorable than Smith & Nephew.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Smith & Nephew	0 Sell rating(s)	6 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
ConvaTec Group	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89

Smith & Nephew has higher revenue and earnings than ConvaTec Group. ConvaTec Group is trading at a lower price-to-earnings ratio than Smith & Nephew, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Smith & Nephew	£7.08B	1.63	£382.79M	£27.77	37.88
ConvaTec Group	£2.49B	1.77	£188.35M	£8.60	26.19

In the previous week, Smith & Nephew and Smith & Nephew both had 2 articles in the media. ConvaTec Group's average media sentiment score of 0.51 beat Smith & Nephew's score of 0.33 indicating that ConvaTec Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Smith & Nephew	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ConvaTec Group	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

62.2% of Smith & Nephew shares are held by institutional investors. Comparatively, 68.4% of ConvaTec Group shares are held by institutional investors. 0.2% of Smith & Nephew shares are held by insiders. Comparatively, 1.0% of ConvaTec Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Smith & Nephew has a net margin of 10.08% compared to ConvaTec Group's net margin of 4.99%. Smith & Nephew's return on equity of 12.25% beat ConvaTec Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Smith & Nephew	10.08%	12.25%	4.51%
ConvaTec Group	4.99%	8.40%	5.01%

Smith & Nephew has a beta of 0.688, meaning that its share price is 31% less volatile than the broader market. Comparatively, ConvaTec Group has a beta of 0.765, meaning that its share price is 24% less volatile than the broader market.

Summary

ConvaTec Group beats Smith & Nephew on 11 of the 17 factors compared between the two stocks.

How does Smith & Nephew compare to Advanced Medical Solutions Group?

Advanced Medical Solutions Group (LON:AMS) and Smith & Nephew (LON:SN) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, media sentiment, dividends, analyst recommendations and institutional ownership.

Advanced Medical Solutions Group has a beta of 0.704, indicating that its share price is 30% less volatile than the broader market. Comparatively, Smith & Nephew has a beta of 0.688, indicating that its share price is 31% less volatile than the broader market.

Advanced Medical Solutions Group presently has a consensus price target of GBX 270.25, indicating a potential downside of 3.83%. Smith & Nephew has a consensus price target of GBX 1,310, indicating a potential upside of 24.52%. Given Smith & Nephew's higher probable upside, analysts plainly believe Smith & Nephew is more favorable than Advanced Medical Solutions Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Advanced Medical Solutions Group	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
Smith & Nephew	0 Sell rating(s)	6 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Smith & Nephew has a net margin of 10.08% compared to Advanced Medical Solutions Group's net margin of 4.35%. Smith & Nephew's return on equity of 12.25% beat Advanced Medical Solutions Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Advanced Medical Solutions Group	4.35%	3.87%	2.35%
Smith & Nephew	10.08%	12.25%	4.51%

Advanced Medical Solutions Group pays an annual dividend of GBX 2.68 per share and has a dividend yield of 1.0%. Smith & Nephew pays an annual dividend of GBX 29 per share and has a dividend yield of 2.8%. Advanced Medical Solutions Group pays out 59.3% of its earnings in the form of a dividend. Smith & Nephew pays out 104.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

22.7% of Advanced Medical Solutions Group shares are held by institutional investors. Comparatively, 62.2% of Smith & Nephew shares are held by institutional investors. 4.0% of Advanced Medical Solutions Group shares are held by insiders. Comparatively, 0.2% of Smith & Nephew shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Smith & Nephew has higher revenue and earnings than Advanced Medical Solutions Group. Smith & Nephew is trading at a lower price-to-earnings ratio than Advanced Medical Solutions Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Advanced Medical Solutions Group	£228.94M	2.67	£11.22M	£4.52	62.17
Smith & Nephew	£7.08B	1.63	£382.79M	£27.77	37.88

In the previous week, Smith & Nephew had 2 more articles in the media than Advanced Medical Solutions Group. MarketBeat recorded 2 mentions for Smith & Nephew and 0 mentions for Advanced Medical Solutions Group. Smith & Nephew's average media sentiment score of 0.33 beat Advanced Medical Solutions Group's score of 0.00 indicating that Smith & Nephew is being referred to more favorably in the news media.

Company	Overall Sentiment
Advanced Medical Solutions Group	Neutral
Smith & Nephew	Neutral

Summary

Smith & Nephew beats Advanced Medical Solutions Group on 12 of the 18 factors compared between the two stocks.

How does Smith & Nephew compare to NIOX Group?

NIOX Group (LON:NIOX) and Smith & Nephew (LON:SN) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

In the previous week, Smith & Nephew had 2 more articles in the media than NIOX Group. MarketBeat recorded 2 mentions for Smith & Nephew and 0 mentions for NIOX Group. Smith & Nephew's average media sentiment score of 0.33 beat NIOX Group's score of 0.00 indicating that Smith & Nephew is being referred to more favorably in the news media.

Company	Overall Sentiment
NIOX Group	Neutral
Smith & Nephew	Neutral

NIOX Group has higher earnings, but lower revenue than Smith & Nephew. Smith & Nephew is trading at a lower price-to-earnings ratio than NIOX Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NIOX Group	£48.70M	5.84	£995.88M	£1.64	41.22
Smith & Nephew	£7.08B	1.63	£382.79M	£27.77	37.88

NIOX Group has a beta of 0.92, meaning that its stock price is 8% less volatile than the broader market. Comparatively, Smith & Nephew has a beta of 0.688, meaning that its stock price is 31% less volatile than the broader market.

NIOX Group pays an annual dividend of GBX 1.25 per share and has a dividend yield of 1.8%. Smith & Nephew pays an annual dividend of GBX 29 per share and has a dividend yield of 2.8%. NIOX Group pays out 76.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Smith & Nephew pays out 104.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

7.6% of NIOX Group shares are held by institutional investors. Comparatively, 62.2% of Smith & Nephew shares are held by institutional investors. 5.1% of NIOX Group shares are held by company insiders. Comparatively, 0.2% of Smith & Nephew shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

NIOX Group has a net margin of 14.37% compared to Smith & Nephew's net margin of 10.08%. Smith & Nephew's return on equity of 12.25% beat NIOX Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NIOX Group	14.37%	10.14%	3.95%
Smith & Nephew	10.08%	12.25%	4.51%

NIOX Group currently has a consensus price target of GBX 86, suggesting a potential upside of 27.22%. Smith & Nephew has a consensus price target of GBX 1,310, suggesting a potential upside of 24.52%. Given NIOX Group's stronger consensus rating and higher possible upside, analysts plainly believe NIOX Group is more favorable than Smith & Nephew.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NIOX Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Smith & Nephew	0 Sell rating(s)	6 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

NIOX Group and Smith & Nephew tied by winning 9 of the 18 factors compared between the two stocks.

How does Smith & Nephew compare to Tristel?

Tristel (LON:TSTL) and Smith & Nephew (LON:SN) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, media sentiment, valuation, profitability and institutional ownership.

Tristel pays an annual dividend of GBX 14.20 per share and has a dividend yield of 3.5%. Smith & Nephew pays an annual dividend of GBX 29 per share and has a dividend yield of 2.8%. Tristel pays out 87.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Smith & Nephew pays out 104.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Tristel is clearly the better dividend stock, given its higher yield and lower payout ratio.

Smith & Nephew has higher revenue and earnings than Tristel. Tristel is trading at a lower price-to-earnings ratio than Smith & Nephew, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tristel	£49.54M	3.98	£6.54M	£16.24	25.31
Smith & Nephew	£7.08B	1.63	£382.79M	£27.77	37.88

Smith & Nephew has a consensus target price of GBX 1,310, suggesting a potential upside of 24.52%. Given Smith & Nephew's stronger consensus rating and higher possible upside, analysts plainly believe Smith & Nephew is more favorable than Tristel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tristel	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Smith & Nephew	0 Sell rating(s)	6 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

22.5% of Tristel shares are held by institutional investors. Comparatively, 62.2% of Smith & Nephew shares are held by institutional investors. 21.0% of Tristel shares are held by insiders. Comparatively, 0.2% of Smith & Nephew shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Tristel has a beta of 0.346, meaning that its share price is 65% less volatile than the broader market. Comparatively, Smith & Nephew has a beta of 0.688, meaning that its share price is 31% less volatile than the broader market.

Tristel has a net margin of 15.88% compared to Smith & Nephew's net margin of 10.08%. Tristel's return on equity of 23.64% beat Smith & Nephew's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tristel	15.88%	23.64%	9.89%
Smith & Nephew	10.08%	12.25%	4.51%

In the previous week, Smith & Nephew had 2 more articles in the media than Tristel. MarketBeat recorded 2 mentions for Smith & Nephew and 0 mentions for Tristel. Smith & Nephew's average media sentiment score of 0.33 beat Tristel's score of 0.00 indicating that Smith & Nephew is being referred to more favorably in the news media.

Company	Overall Sentiment
Tristel	Neutral
Smith & Nephew	Neutral

Summary

Smith & Nephew beats Tristel on 11 of the 18 factors compared between the two stocks.

How does Smith & Nephew compare to INSPECS Group?

Smith & Nephew (LON:SN) and INSPECS Group (LON:SPEC) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings.

Smith & Nephew has a beta of 0.688, suggesting that its stock price is 31% less volatile than the broader market. Comparatively, INSPECS Group has a beta of 1.607, suggesting that its stock price is 61% more volatile than the broader market.

Smith & Nephew has a net margin of 10.08% compared to INSPECS Group's net margin of -2.67%. Smith & Nephew's return on equity of 12.25% beat INSPECS Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Smith & Nephew	10.08%	12.25%	4.51%
INSPECS Group	-2.67%	-6.07%	0.45%

Smith & Nephew presently has a consensus price target of GBX 1,310, suggesting a potential upside of 24.52%. INSPECS Group has a consensus price target of GBX 60, suggesting a potential downside of 35.31%. Given Smith & Nephew's higher probable upside, research analysts clearly believe Smith & Nephew is more favorable than INSPECS Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Smith & Nephew	0 Sell rating(s)	6 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
INSPECS Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Smith & Nephew has higher revenue and earnings than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than Smith & Nephew, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Smith & Nephew	£7.08B	1.63	£382.79M	£27.77	37.88
INSPECS Group	£191.70M	0.53	-£4.11M	-£9.40	N/A

62.2% of Smith & Nephew shares are owned by institutional investors. Comparatively, 0.7% of INSPECS Group shares are owned by institutional investors. 0.2% of Smith & Nephew shares are owned by company insiders. Comparatively, 19.6% of INSPECS Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Smith & Nephew had 2 more articles in the media than INSPECS Group. MarketBeat recorded 2 mentions for Smith & Nephew and 0 mentions for INSPECS Group. Smith & Nephew's average media sentiment score of 0.33 beat INSPECS Group's score of 0.00 indicating that Smith & Nephew is being referred to more favorably in the media.

Company	Overall Sentiment
Smith & Nephew	Neutral
INSPECS Group	Neutral

Summary

Smith & Nephew beats INSPECS Group on 13 of the 16 factors compared between the two stocks.

Get Smith & Nephew News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SN vs. The Competition

Export

Metric	Smith & Nephew	Healthcare Equipment & Supplies Industry	Healthcare Sector	LON Exchange
Market Cap	£11.53B	£5.58B	£7.17B	£2.91B
Dividend Yield	3.66%	1.76%	2.53%	6.18%
P/E Ratio	37.88	25.84	272.99	367.42
Price / Sales	1.63	44.74	612.73	83,891.79
Price / Cash	18.68	33.14	77.82	27.89
Price / Book	1.77	6.06	12.85	6.75
Net Income	£382.79M	£149.47M	£3.47B	£5.89B
7 Day Performance	-1.91%	-1.30%	1.24%	5.57%
1 Month Performance	-12.11%	1.33%	5.81%	2.30%
1 Year Performance	-24.26%	10.29%	25.75%	21.81%

Smith & Nephew Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SN Smith & Nephew	4.3197 of 5 stars	GBX 1,052 -1.0%	GBX 1,310 +24.5%	-22.8%	£11.53B	£7.08B	37.88	18,452	Negative News Gap Up High Trading Volume
CTEC ConvaTec Group	4.5325 of 5 stars	GBX 233 +1.4%	GBX 306 +31.3%	-3.6%	£4.55B	£2.49B	27.09	10,000	News Coverage
AMS Advanced Medical Solutions Group	N/A	GBX 281.08 +0.2%	GBX 270.25 -3.9%	+36.1%	£611.62M	£228.94M	62.19	10
NIOX NIOX Group	N/A	GBX 67.58 -0.6%	GBX 86 +27.3%	-8.4%	£284.43M	£48.70M	41.21	92
TSTL Tristel	N/A	GBX 397.25 -4.3%	N/A	+14.6%	£190.67M	£49.54M	24.46	208	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:SN) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Smith & Nephew (SN) Competitors

SN vs. CTEC, AMS, NIOX, TSTL, and SPEC

How does Smith & Nephew compare to ConvaTec Group?

Summary

How does Smith & Nephew compare to Advanced Medical Solutions Group?

Summary

How does Smith & Nephew compare to NIOX Group?

Summary

How does Smith & Nephew compare to Tristel?

Summary

How does Smith & Nephew compare to INSPECS Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SN vs. The Competition

Smith & Nephew Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Smith & Nephew (SN) Competitors

SN vs. CTEC, AMS, NIOX, TSTL, and SPEC

How does Smith & Nephew compare to ConvaTec Group?

Is SN or CTEC a better dividend stock?

Do analysts recommend SN or CTEC?

Which has preferable earnings and valuation, SN or CTEC?

Does the media favor SN or CTEC?

Do insiders & institutionals have more ownership in SN or CTEC?

Is SN or CTEC more profitable?

Which has more volatility & risk, SN or CTEC?

Summary

How does Smith & Nephew compare to Advanced Medical Solutions Group?

Which has more risk & volatility, AMS or SN?

Do analysts prefer AMS or SN?

Is AMS or SN more profitable?

Is AMS or SN a better dividend stock?

Do institutionals and insiders hold more shares of AMS or SN?

Which has better earnings and valuation, AMS or SN?

Does the media favor AMS or SN?

Summary

How does Smith & Nephew compare to NIOX Group?

Does the media refer more to NIOX or SN?

Which has better valuation & earnings, NIOX or SN?

Which has more risk and volatility, NIOX or SN?

Is NIOX or SN a better dividend stock?

Do institutionals & insiders have more ownership in NIOX or SN?

Is NIOX or SN more profitable?

Do analysts recommend NIOX or SN?

Summary

How does Smith & Nephew compare to Tristel?

Is TSTL or SN a better dividend stock?

Which has preferable valuation and earnings, TSTL or SN?

Do analysts rate TSTL or SN?

Do insiders and institutionals have more ownership in TSTL or SN?

Which has more risk & volatility, TSTL or SN?

Is TSTL or SN more profitable?

Does the media refer more to TSTL or SN?

Summary

How does Smith & Nephew compare to INSPECS Group?

Which has more volatility & risk, SN or SPEC?

Is SN or SPEC more profitable?

Do analysts prefer SN or SPEC?

Which has preferable earnings and valuation, SN or SPEC?

Do insiders and institutionals have more ownership in SN or SPEC?

Does the media favor SN or SPEC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SN vs. The Competition

Smith & Nephew Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools